RETEVMO
Identification of Retevmo
| No description |
Google image searchProduct monograph
Active ingredient
selpercatinib, 80 MG
DIN: 02516926
Dosage form(s): CAPSULE
Route(s) of administration: ORAL
Schedule: Prescription
Company: LOXO ONCOLOGY INC
Date: 21-JAN-2022
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EX — Other protein kinase inhibitors (ATC, ATC/DDD)
- L01EX22 — SELPERCATINIB (ATC/DDD)
Reference brand drug: Retevmo
